Software sells off, FDA Commissioner on revised food dye regulations

Key Concepts

• Market Correction: A broad decline in stock prices, particularly impacting tech and software sectors.
• AI Impact on Software: Concerns that advancements in Artificial Intelligence will disrupt traditional software models and valuations.
• Crypto Winter: A prolonged period of declining cryptocurrency prices.
• FDA Reforms: Changes to food labeling regulations (artificial dyes) and drug approval processes (expedited voucher program).
• Terminal Value Risk: The risk that future growth expectations for a company are overly optimistic, leading to a decline in valuation.
• Rotation Trade: Shifting investments between different asset classes (e.g., from US stocks to bonds).
• TAM Expansion: Total Addressable Market expansion – the potential for increased revenue due to new opportunities.

Market Trends & Tech Sector Decline

The stock market is experiencing a downturn, with the S&P 500 erasing its 2026 gains. Major averages are down across the board, particularly impacting the tech sector. The NASDAQ is down 1.6% and the Dow Jones Industrial Average is down 1.2%. The Russell 2000 is also experiencing late-day selling pressure. However, bonds and the US dollar index are showing some gains, resembling a “deepseek moment” from the previous year when stocks were considered overvalued. The S&P 500 is now negative for the year, with the tech sector down 6% year-to-date. Other sectors like financials, consumer discretionary, and communication services are also experiencing declines. Despite the overall negative trend, the DJT (Transportation Index) is up 12% and chip stocks remain in positive territory.

Cryptocurrency Market Crash

The cryptocurrency market is in a significant downturn, officially entering a “crypto winter.” Bitcoin has been cut in half from its 2025 high, falling to $62,000 after previously hitting $75,000. Mark Newton of Fundstrat predicts Bitcoin could fall to the high 50s or 60s, while 10x Research suggests a potential drop into the 40s, with a bottom likely between summer and September. This mirrors the crypto winter of 2022, with a potential for a prolonged period of decline.

Metals Market Volatility

The metals market is also experiencing volatility, with silver probing new lows and experiencing a 37% decline year-to-date. A recent bounce back has been partially reversed. This decline is occurring alongside the crypto downturn, potentially indicating a broader risk-off sentiment.

Software Sector Under Pressure from AI

The software sector is facing significant pressure due to the rapid advancements in Artificial Intelligence (AI). Dan Eisler of Wedbush has described the situation as a “software Armageddon.” Richishy Gela of RBC Capital Markets acknowledges the reality behind the AI hype but argues that the idea of AI being the “death of software” is incorrect. He believes the pullback is an overreaction presenting buying opportunities, emphasizing the importance of investing in innovative, high-quality companies.

The core concern is that companies will build their own AI agents to perform functions traditionally handled by software tools, or that functionality will be subsumed into platforms like OpenAI and Anthropic. Gela argues this isn’t a zero-sum game, and AI will ultimately expand the Total Addressable Market (TAM) for software. He notes that earnings numbers for software companies haven’t actually declined, suggesting the current market reaction is driven by “terminal value risk” – concerns about long-term growth prospects. He highlights HubSpot and MongoDB as potential buying opportunities, citing their innovation and ability to leverage AI.

Notable Quote (Richishy Gela): “This pullback is a huge overreaction. I think it's presenting some really great buying opportunities. But I think we need to put on our thinking caps and really scrutinize what are the companies that are going to recover the best. Like this is the opportunity to invest in quality.”

FDA Reforms: Food Labeling & Drug Approvals

The Food and Drug Administration (FDA) is implementing changes to food labeling and drug approval processes. The FDA is addressing inaccuracies in “no artificial dyes” labeling, recognizing the role of natural colorings. They have approved two additional natural dyes and are working to remove all nine petroleum-based dyes from the US food supply, with 40% of the food industry already pledging to comply. The FDA banned one artificial dye with the strongest health concerns and is encouraging voluntary removal from food products, while reserving the right to use its ban authority if necessary.

The FDA is also implementing an expedited voucher program to accelerate drug approvals, reducing the time to market from 10-12 months to 1-2 months. This program has awarded 15 vouchers so far. While controversial, the FDA Commissioner emphasizes that this is about reducing “idle time” in the process, not cutting corners on safety. The agency is hiring 1,500 scientists to support its reform agenda.

Notable Quote (FDA Commissioner): “We’re reducing idle time. There's a lot of idle time in the process…We're not cutting any corners on safety.”

Logical Connections

The discussion flows from a broad overview of market trends (stock declines, crypto crash, metals volatility) to a deeper dive into specific sectors (tech, software, crypto). The software sector analysis is directly linked to the broader AI narrative, explaining the market’s concerns and potential opportunities. The segment then shifts to a completely different topic – FDA reforms – demonstrating the program’s coverage of diverse economic and regulatory developments. The common thread throughout is the identification of trends and their potential impact on investment strategies.

Data & Statistics

• S&P 500: Down for the year 2026.
• Dow Jones Industrial Average: Down 1.2%
• NASDAQ: Down 1.6%
• Bitcoin: Down 50% from its 2025 high (currently at $62,000, previously at $75,000).
• Silver: Down 37% year-to-date.
• HubSpot: Down 70% over the past 12 months.
• MongoDB: Down 20% this year.
• IntoIt: Down 30% this year.
• FDA IT Personnel Reduction: From 1,500 to 700.
• FDA HR & Procurement Staff Reduction: From 2,000 to a couple hundred.
• FDA New Scientist Hires: 1,500 planned, with 110 already in seats and 400 being onboarded.

Conclusion

The market is currently navigating a period of uncertainty, with significant declines in tech, crypto, and metals. The rise of AI is creating both challenges and opportunities for the software sector, requiring investors to focus on innovation and quality. The FDA is implementing reforms aimed at improving transparency in food labeling and accelerating drug approvals. Investors should remain cautious, scrutinize valuations, and focus on companies with strong fundamentals and the ability to adapt to evolving technological landscapes. The key takeaway is to identify trends early and position portfolios accordingly, while recognizing the potential for both overreactions and long-term growth opportunities.